Other functions - R & D biomedical (basic research)

Ended Definitive Contract Awarded Sep 18, 2012 Last action Jul 15, 2018

Contract number: HHSN261201200076C
Awardee: Cellerant Therapeutics, Inc. UEI LML1YE6L8KU3
Awarding agency: National Cancer Institute National Institutes of Health, Department of Health and Human Services
Obligated: $1,659,423

Award facts

Opportunity: PHS20121 Solicitation number

A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Award Notice · Posted Aug 5, 2011
Contract value 100% obligated: $1,659,422.71 Current and potential, with all options
Completion date 100% complete: Jul 20, 2017 Current and potential, with all options
NAICS code: 541711 Research and Development in Biotechnology
PSC: AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside: Total Small Business
Competition: Full and Open Competition after exclusion of sources · 18 offers Negotiated Proposal / Quote
Pricing: Firm Fixed Price
Place of performance: San Carlos, CA 94070, USA
Research: SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action	Obligated	Date
Funding Only Action 10	-$24,080	Jul 15, 2018
Other Administrative Action 9	$0	Apr 26, 2017
Other Administrative Action 8	$0	Jul 18, 2016
Other Administrative Action 7	$0	Apr 11, 2016
Other Administrative Action 6	$0	Oct 29, 2015
Other Administrative Action 5 · Development of a process for generating human mkpperiod of performance: 09/20/2012 - 06/19/2015	$0	May 20, 2015
Other Administrative Action 4 · TAS::750849::tasother functions	$0	Sep 23, 2014
Exercise an Option 3 · Development of a process for generating human MKP other functions other functions	$1,489,036	Aug 6, 2013
Other Administrative Action 2 · Development of a process for generating human MKP other functions	$0	Jun 25, 2013
Other Administrative Action 1 · Other functions development of a process for generating human MKP	$0	May 17, 2013
Original award	$194,467	Sep 18, 2012

Show all 11

About this award

Written by GovTribe AI · Mar 11, 2026

The National Cancer Institute (NCI) awarded a $1.66 million firm fixed-price definitive contract to Cellerant Therapeutics, Inc., a small business, on September 20, 2012. The contract, designated as a Total Small Business set-aside, supports basic biomedical research and development activities, with performance conducted at the contractor's facility in San Carlos, California. The contract was completed on June 19, 2015.

This award reflects NCI's commitment to funding innovative early-stage research through small business partnerships. Cellerant Therapeutics' work under this contract contributed to the Institute's broader mission of advancing cancer research and therapeutic development through extramural funding mechanisms that encourage participation from smaller organizations capable of conducting specialized biomedical research.

Quick answers

Who was awarded contract HHSN261201200076C?

HHSN261201200076C was awarded to Cellerant Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2012.

How much is contract HHSN261201200076C worth?

The government has obligated $1,659,423 on HHSN261201200076C.

Was contract HHSN261201200076C competed?

The extent of competition for HHSN261201200076C was full and open competition after exclusion of sources. The government received 18 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

Every transaction and funding action
The awardee's other awards and teaming partners
Similar awards and recompete opportunities
Ask GovTribe AI about this award

Try for free Login